期刊
JOURNAL OF BONE AND MINERAL RESEARCH
卷 37, 期 5, 页码 826-836出版社
WILEY
DOI: 10.1002/jbmr.4549
关键词
GENE THERAPY; CELL THERAPY; OSTEOGENESIS IMPERFECTA; COLLAGEN
资金
- Teicke Foundation
- Flicker of Hope Foundation
- Sydney Children's Hospitals Foundation
- Care 4 Brittle Bones Foundation
- Sticks and Stones Foundation
- Children's Tumor Foundation
This article discusses emerging technologies in cell and gene-targeted therapies, major challenges in implementing these treatment methods, and prospects for their future success in bone disorders.
Osteogenesis imperfecta (OI) describes a series of genetic bone fragility disorders that can have a substantive impact on patient quality of life. The multidisciplinary approach to management of children and adults with OI primarily involves the administration of antiresorptive medication, allied health (physiotherapy and occupational therapy), and orthopedic surgery. However, advances in gene editing technology and gene therapy vectors bring with them the promise of gene-targeted interventions to provide an enduring or perhaps permanent cure for OI. This review describes emergent technologies for cell- and gene-targeted therapies, major hurdles to their implementation, and the prospects of their future success with a focus on bone disorders. (c) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据